Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2014 at the end of the period of market exclusivity.
On 30 July 2001, orphan designation (EU/3/01/050) was granted by the European Commission to Orphan Europe s.a.r.l., France, for zinc acetate dihydrate for the treatment of Wilson's disease.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
- What is Wilson's disease?
Wilson's disease is a genetic disorder that causes excessive copper accumulation in the body, typically in the liver and brain. The liver of a person who has Wilson's disease does not release copper into the bile, as it should. Bile is a liquid produced by the liver that helps with digestion. In Wilson’s disease, the copper that is normally absorbed from the food by the intestines builds up in the liver and injures liver tissue. Eventually, the damage causes the liver to release the copper directly into the bloodstream, which carries the copper throughout the body. The copper accumulated and transported by the bloodstream can then cause damage in other organs like the kidneys, brain, and eyes. If not treated, Wilson's disease can be chronically debilitating and life threatening.
- What is the estimated number of patients affected by the condition?
At the time of designation, Wilson’s disease affected approximately 0.6 in 10,000 people in the European Union (EU). This was equivalent to a total of around 23,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union.
At the time of designation, this represented a population of 378,800,000 (Eurostat 2001).
- What treatments are available?
Treatment of Wilson's disease generally consisted of anti-copper agents to remove excess copper from the body and to prevent it from re-accumulating. Several medicinal products were authorised for Wilson’s disease in the Community at the time of submission of the application for orphan drug designation.
Satisfactory argumentation has been provided by the sponsor to justify that zinc acetate dihydrate could be of potential significant benefit for the treatment of Wilson's disease because it could contribute to the existing patient care. This assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- How is this medicine expected to work?
Zinc acetate dihydrate blocks the absorption of copper and increases copper excretion in the stool.
- What is the stage of development of this medicine?
The effects of zinc acetate have been evaluated in experimental models. At the time of submission, clinical trials in patients with Wilson’s disease were ongoing.
At the time of submission, zinc acetate was not authorised anywhere in the Community for Wilson’s disease. Orphan designation of zinc acetate had been granted in the United States for Wilson’s disease.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 12 June 2001 recommending the granting of this designation.
Update: Zinc acetate dihydrate (Wilzin) has been authorised in the EU since 13 October 2004 for treatment of Wilson's disease.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/01/050: Public summary of positive opinion for orphan designation of zinc acetate dihydrate for the treatment of Wilson's disease||(English only)||03/03/2009||06/03/2015|
|Active substance||Zinc acetate dihydrate|
|Disease/condition||Treatment of Wilson’s disease|
|Date of decision||31/07/2001|
|Orphan decision number||EU/3/01/050|
Review of designation
Sponsor’s contact details
Orphan Europe SARL
Immeuble Le Wilson
70 Avenue du Général de Gaulle
Tel. +33 1 4773 6458
Fax +33 1 49 00 18 00
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.